DSIP

Despite fifty years of work, DSIP has no identified receptor and no accepted signalling pathway, which is the single most important thing to know about it. The proposed mechanisms are all indirect: modulation of GABAergic and serotonergic tone, suppression of corticotropin-releasing hormone and ACTH output, interaction with opioid systems, and a permissive effect on pineal melatonin synthesis. Human sleep-lab work showed changes in sleep continuity and efficiency rather than a straightforward hypnotic knock-out effect, which fits a regulatory rather than sedative role. Treat every mechanistic claim here as proposed, not established.

Targets: Hypothalamic-pituitary-adrenal axis (CRH/ACTH suppression, proposed), GABAergic and serotonergic arousal circuits (proposed), Opioid receptor systems (proposed), No identified high-affinity receptor

• · Almost everyone starts at 100 mcg and only moves up if nothing happens. Above roughly 500 mcg the main reports are headache and next-morning grogginess, not better sleep.
• · The 1980s human trials used 25 nmol/kg intravenously, which works out to about 21 mcg/kg — roughly 1.5 mg for a 70 kg adult. This is five to ten times the typical subcutaneous community dose and is listed for context, not as a home protocol.
• · Bioavailability by this route has never been quantified for DSIP, so the higher numbers are compensating for an unknown loss rather than reflecting a measured equivalence.

Work out your exact syringe units →

• commonMorning grogginess or a heavy, hungover feeling— Strongly dose-dependent; usually resolves by dropping the dose.
• commonHeadache— Often reported in the first few nights and on higher doses.
• commonInjection-site stinging or redness— Transient, typical of any subcutaneous peptide.
• uncommonTransient dizziness or a drop in blood pressure— Mostly reported with larger doses; stand up slowly.
• uncommonVivid or unusually intense dreams— Some users count this as a feature.
• uncommonParadoxical restlessness or wired-but-tired feeling— Reported by a minority; usually means the dose is too high.

• Untreated obstructive sleep apnoea - anything that deepens sleep can worsen respiratory events, and DSIP does nothing for the airway.
• Combining with alcohol, benzodiazepines, Z-drugs or opioids at the same time of night - the sedation stacks unpredictably and no interaction data exist.
• Pregnancy and breastfeeding - zero data.
• Driving or on-call duty within 8 hours of a dose until you know how you personally respond.

• synergyepitalon-circadian — Commonly stacked in circadian protocols — Epitalon aims at the melatonin rhythm over weeks while DSIP acts on a single night.
• synergyselank-anxiolytic — Pairs logically for people whose insomnia is anxiety-driven rather than rhythm-driven.
• cautionmk-677 — Both are used to increase slow-wave sleep, so the combination is redundant on that axis while MK-677 adds appetite, water retention and its own vivid-dream burden.
• conflictorexin-a-wake — Directly opposing intentions — one promotes sleep, the other promotes wakefulness. Do not run them on the same clock.

• · Track sleep with a wearable or a simple sleep diary — subjective impressions of deep sleep are notoriously unreliable.
• · Watch morning alertness for the first week; a groggy morning is the main signal to cut the dose.
• · No routine bloodwork is established or needed.

Not approved as a medicine anywhere. Sold worldwide as a research chemical; possession and use for personal purposes sit in a legal grey zone in most jurisdictions.

• Schneider-Helmert & Schoenenberger 1981, influence of synthetic DSIP on disturbed human sleep (trial)
• Schneider-Helmert 1987, short-term DSIP administration to chronic insomniacs (trial)
• Graf & Kastin 1984, DSIP: an update review (review)
• Kovalzon & Strekalova 2006, delta sleep-inducing peptide reappraisal (review)

The honest version is that DSIP is a peptide in search of a receptor. Fifty years after Monnier and Schoenenberger dialysed it out of the cerebral venous blood of electrically sleep-induced rabbits, there is still no cloned receptor, no established second messenger and no accepted signalling cascade. Kovalzon and Strekalova's 2006 review in the Journal of Neurochemistry is titled 'a still unresolved riddle', and that remains the state of the field. What does have experimental support is an effect on the stress axis. Graf, Kastin and colleagues showed in 1985 that DSIP reduces CRF-induced corticosterone release, which places its action upstream of or at the pituitary rather than at a hypnotic receptor. That fits the clinical picture better than a sedative model does. In Schneider-Helmert's human work DSIP did not knock people out the way a benzodiazepine does. It improved sleep continuity, shortened sleep latency modestly, and improved daytime alertness in chronic insomniacs. The 1987 24-hour study in severe chronic insomnia found the effect distributed across the whole sleep-wake cycle rather than concentrated in the hour after dosing. That is the signature of a regulator, not a hypnotic. Brain penetration is real but modest and passive. Kastin and Banks demonstrated differential penetration of DSIP and its analogues into rat brain and later measured entry into dog CSF as a function of physicochemical properties, concluding that transport is largely by non-saturable diffusion driven by lipophilicity rather than by a dedicated carrier. In plain terms: some of an injected dose gets into brain, the fraction is small, and it is not being actively pumped in. The mismatch that defines this compound is that the molecule is gone from plasma in minutes while the reported sleep effect appears the same night and, in several of the human studies, kept improving over subsequent nights. Whatever DSIP does, it is triggering something rather than occupying something.

The three things that actually go wrong with DSIP, in order of how often they happen. One: people dose too high and wake up feeling drugged. This is the dominant failure mode and it is entirely avoidable. The relationship between dose and benefit is not monotonic - 100 mcg often works better than 400 mcg, and the heavy, hungover morning is the signal that you have gone past the useful range. The instinct when a sleep aid does not work is to take more, and with DSIP that instinct is wrong. Two: the effect fades. A large fraction of people report DSIP working well for one to three weeks and then doing progressively less. There is no mechanistic explanation for this because there is no mechanism, and there is no receptor to downregulate. It may be tachyphylaxis, it may be regression to the mean after a good week, it may be that the initial effect was expectation. Either way the community answer - five nights on and two off, or blocks of two to four weeks with a week's break - costs nothing and is worth doing from the start rather than after the effect has already gone. Three: people use it to paper over something that needs actual diagnosis. Untreated sleep apnoea is the big one. DSIP does nothing for an airway, and anything that makes you sleep more deeply is at best neutral and at worst harmful if you stop breathing forty times an hour. If you snore, wake unrefreshed, or have a neck circumference over 43 cm, get a home sleep study before you get a vial. The same applies to a ferritin of 15 and a TSH of 8. The smaller ones: dosing at the wrong time (DSIP wants 30 to 60 minutes of lead time, not five), measuring a 100 mcg dose out of an over-concentrated vial and being off by fifty percent, and leaving a reconstituted vial on the nightstand where it degrades in warmth and light.

1. 100 mcgNights 1 to 4 — Start here regardless of what the vendor label says. Dose 30 to 60 minutes before lights out. Judge on morning alertness, not on how fast you fell asleep.
2. 200 mcgNights 5 to 8 — Only move up if 100 mcg produced nothing at all across four nights. If 100 mcg worked, stay there - this is not a compound where more is better.
3. 300 mcgNights 9 to 12 — The top of the sensible community range. Most people who get an effect get it at or below this.
4. 500 mcgBeyond night 12 — The practical ceiling. Above roughly 500 mcg the consistent report is headache and next-morning heaviness rather than deeper sleep. If 500 mcg does nothing, DSIP is not working for you and the answer is to stop, not to escalate.

• No identified high-affinity receptor — None established

  This is the central fact about DSIP. No binding site has been cloned, no saturable specific binding has been convincingly demonstrated, and no orphan GPCR has been deorphanised to DSIP. Every downstream claim below is a functional observation without a molecular anchor.

• CRF-driven HPA axis output — Not a binding interaction; a functional antagonism

  DSIP reduced CRF-induced corticosterone release in rats (Graf, Kastin, Coy and Fischman, Neuroendocrinology 1985). Damping the evening tail of the stress axis is the most plausible mechanistic account of why it helps people whose insomnia is arousal-driven.

• Opioid and enkephalin systems — Not characterised

  Proposed on the basis of naloxone-sensitivity in some animal paradigms. Never pinned to a receptor subtype. Treat as a hypothesis.

• Pineal melatonin synthesis — Not characterised

  A permissive or facilitatory effect on melatonin output has been proposed repeatedly and demonstrated cleanly nowhere. It is the mechanism most often quoted by vendors and the one with the least support.

• GABAergic and serotonergic arousal circuits — Not characterised

  Inferred from behavioural pharmacology and from analogy with other sleep peptides. No direct receptor-level demonstration exists.

• Schneider-Helmert and Schoenenberger, influence of synthetic DSIP on disturbed human sleep (Experientia 1981) Investigator-initiated sleep-laboratory study, not phase-labelled · 1981

  Polysomnographic sleep variables in subjects with disturbed sleep after intravenous synthetic DSIP. The first human demonstration that synthetic DSIP altered sleep in people rather than rabbits.

• Schneider-Helmert, Graf and Schoenenberger, synthetic DSIP improves sleep in insomniacs (Lancet 1981) Investigator-initiated, not phase-labelled · 1981

  Improvement in sleep in insomniac subjects given synthetic DSIP. Notable mainly because it is the one DSIP result that landed in a major general journal.

• Schneider-Helmert and Schoenenberger, effects of DSIP in man - multifunctional psychophysiological properties besides induction of natural sleep (Neuropsychobiology 1983) Investigator-initiated, not phase-labelled · 1983

  Sleep and daytime psychophysiological measures. The title is the finding: DSIP did more than induce sleep, which is the earliest clear statement that this is a regulator rather than a hypnotic.

• Schneider-Helmert, efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs (European Neurology 1986) Investigator-initiated, not phase-labelled · 1986

  Normalisation of polysomnographic sleep in middle-aged and elderly chronic insomniacs. This is the study most often cited as the strongest positive DSIP result.

• Schneider-Helmert, effects of DSIP on 24-hour sleep-wake behaviour in severe chronic insomnia (European Neurology 1987) Investigator-initiated, not phase-labelled · 1987

  Sleep and wake measures across a full 24-hour cycle rather than a single night. Important because it showed the effect was not confined to the hours after dosing.

• Schneider-Helmert, effects of DSIP on narcolepsy (European Neurology 1984) Investigator-initiated, not phase-labelled · 1984

  Sleep and wake measures in narcoleptic patients. Included because it shows the same group testing DSIP across opposite sleep pathologies, which is part of why the literature reads as exploratory rather than confirmatory.

Night one: most people who respond notice something the first night, usually a shorter time to fall asleep and a subjective sense of sleeping through rather than surfacing repeatedly. It is not a knock-out. If you are expecting the thud of a Z-drug you will conclude it did nothing. Nights two to four: the signal to watch here is the morning, not the night. A clear-headed morning at 100 mcg means the dose is right. A heavy morning means drop to 50 mcg or stop. Nights five to fourteen: this is where the human studies reported continued improvement, and where community reports mostly agree. Sleep continuity keeps consolidating. If nothing at all has happened by night ten at 300 mcg, escalating further is unlikely to change the outcome. Weeks three to four: the fade window. If the effect is going to diminish, this is when. Take a week off and reassess rather than raising the dose. Stopping: no withdrawal, no rebound insomnia beyond the ordinary disappointment of losing something that was helping. This is one of the genuine advantages over hypnotics and it is worth stating plainly - there is no dependence syndrome described for DSIP.

DSIP is a single-night tool, which makes it easy to stack coherently as long as you respect that. With Epitalon: the standard circadian pairing and the one that actually makes sense. Epitalon is a 10 to 20 day course aimed at where your melatonin peak sits; DSIP is aimed at tonight. Run Epitalon as its course and use DSIP nightly across the same period if you want, then keep DSIP as the as-needed tool once the course ends. With Selank: the right pairing when the problem is that your head will not stop. Selank at 250 to 500 mcg intranasally one to two hours before bed handles the anxious arousal, DSIP handles the sleep itself. Non-overlapping mechanisms, and Selank does not sedate, so the two do not stack into a heavy morning. With magnesium glycinate, glycine (3 g) or apigenin: no interaction data, no reason to expect a problem, and these are cheap enough that they should be tried before a peptide. With melatonin: mechanistically redundant if you believe the pineal claim and mechanistically independent if you do not. In practice most people who use both find low-dose melatonin (0.3 to 0.5 mg) for timing plus DSIP for depth is not obviously better than either alone. Run them separately for two weeks each before combining. Hard no on the same night as alcohol, benzodiazepines, Z-drugs, gabapentinoids or opioids. Not because there is an interaction study - there is not - but because the failure mode of DSIP is next-morning heaviness and every one of those compounds does the same thing through a mechanism you can actually predict. Hard no with orexin-A on the same clock. If you insist on running both, morning orexin and evening DSIP separated by twelve hours is the only version that is not self-defeating.

Against a Z-drug or benzodiazepine: not comparable in potency and not trying to be. Zolpidem will put you to sleep; DSIP will, at best, make the sleep you were going to have more continuous. What DSIP has that they do not is the absence of a dependence syndrome, no documented rebound insomnia and no next-day cognitive impairment at sensible doses. What they have that DSIP does not is forty years of regulatory-grade efficacy data. Against low-dose melatonin: melatonin is cheaper, oral, better studied for circadian timing, and useless for sleep depth. If your problem is that you fall asleep at 3am, melatonin at 0.3 mg five hours before target bedtime is the correct intervention and DSIP is not. If your problem is that you fall asleep fine and wake up at 4am unrefreshed, melatonin will not help and DSIP might. Against MK-677: MK-677 reliably increases slow-wave sleep in actual polysomnography studies, which is more than DSIP can claim. It also raises appetite, causes water retention, raises fasting glucose and lowers insulin sensitivity. DSIP is the far lighter-touch option with the weaker evidence. Against Epitalon: different problems entirely. Epitalon is for a flattened melatonin rhythm in someone over fifty and works over a course of weeks. DSIP is for tonight. Against trazodone at 25 to 50 mg: trazodone is prescription, cheap, has real data in insomnia, and carries its own morning-grogginess and priapism issues. For most people with genuine chronic insomnia, trazodone or CBT-I is the higher-expected-value move and DSIP is the thing you try after those. Within the sleep peptide class: DSIP has more genuine human polysomnography data than anything else sold in this space. That is a low bar, but it is real, and it is why DSIP sits at the top of a category where most entrants have never seen a sleep lab.

$20–$65/month. Based on a 5 mg vial in the typical grey-market range and a nightly dose of 100 to 300 mcg, which makes one vial last roughly 17 to 50 nights. These are indicative figures from ordinary retail research-chemical pricing rather than a surveyed dataset, and peptide pricing moves a lot. Verify against current listings before budgeting.

• ?No receptor has ever been identified for DSIP. Everything described as a mechanism in this record and everywhere else is a functional observation, not a molecular one.
• ?The commonly quoted 7 to 15 minute human plasma half-life is repeated widely but I could not resolve it to a primary human pharmacokinetic paper in this session. The best hard clearance data I could verify is a 1984 dog study (PMID 6379493). Treat the human figure as approximate.
• ?Bioavailability is unmeasured for subcutaneous, intranasal and sublingual routes. The community intranasal doses of 200 to 500 mcg are compensating for a loss nobody has quantified.
• ?The original human trials used intravenous dosing at roughly 25 nmol/kg. Nobody has ever validated that subcutaneous dosing at one-tenth of that reproduces anything, which is a substantial gap between the evidence and the practice.
• ?Participant numbers, blinding and control conditions for the individual Schneider-Helmert studies were not extracted in this session. They are generally described in secondary sources as small, in the range of roughly five to twenty subjects, and several were open-label. Verify individually before treating any one of them as strong evidence.
• ?The reported tachyphylaxis after two to three weeks is entirely anecdotal. No study has looked for tolerance to DSIP.
• ?Whether DSIP affects human cortisol in the way it affects rat corticosterone has not been tested. The bloodwork recommendation for cortisol is mechanistic inference, not an established monitoring requirement.
• ?The pineal melatonin claim, which is the one vendors lean on hardest, has the least supporting evidence of any of the proposed mechanisms.
• ?Molecular weight of 848.8 Da was confirmed by calculation from the WAGGDASGE sequence rather than from a cited analytical measurement.
• ?Cost figures are indicative retail observations, not sourced or surveyed data.

• The influence of synthetic DSIP (delta-sleep-inducing-peptide) on disturbed human sleep Schneider-Helmert D, Schoenenberger GA, Experientia, 1981 · PMID 7028502

  The foundational human sleep-laboratory report on synthetic DSIP, 37(9):913-7.

• Synthetic delta-sleep-inducing peptide improves sleep in insomniacs Schneider-Helmert D, Graf M, Schoenenberger GA, Lancet, 1981 · PMID 6112579

  Lancet 1(8232):1256-7. The highest-profile venue any DSIP result ever reached.

• Effects of DSIP in man. Multifunctional psychophysiological properties besides induction of natural sleep Schneider-Helmert D, Schoenenberger GA, Neuropsychobiology, 1983 · PMID 6689058

  Neuropsychobiology 9(4):197-206. The clearest early statement that DSIP is not a straightforward hypnotic.

• Efficacy of DSIP to normalize sleep in middle-aged and elderly chronic insomniacs Schneider-Helmert D, European Neurology, 1986 · PMID 3792404

  Eur Neurol 25(6):448-53. The most commonly cited positive efficacy result.

• Effects of delta-sleep-inducing peptide on 24-hour sleep-wake behaviour in severe chronic insomnia Schneider-Helmert D, European Neurology, 1987 · PMID 3622582

  Eur Neurol 27(2):120-9. Shows the effect distributed across the whole 24-hour cycle.

• Acute and delayed effects of DSIP (delta sleep-inducing peptide) on human sleep behavior Schneider-Helmert D, Gnirss F, Monnier M, Schenker J, Schoenenberger GA, International Journal of Clinical Pharmacology, Therapy and Toxicology, 1981 · PMID 6895513

  Int J Clin Pharmacol Ther Toxicol 19(8):341-5. The 'delayed effects' framing is the origin of the claim that DSIP keeps working over subsequent nights.

• Delta-sleep-inducing peptide (DSIP): an update Graf MV, Kastin AJ, Peptides, 1986 · PMID 3550726

  Peptides 7(6):1165-87. The most complete critical review of the first decade of DSIP work, written by people who were not invested in the compound succeeding.

• Delta sleep-inducing peptide (DSIP): a still unresolved riddle Kovalzon VM, Strekalova TV, Journal of Neurochemistry, 2006 · PMID 16539679

  J Neurochem 97(2):303-9. The modern reappraisal, and the reference to read if you only read one. The title is the conclusion.

• Delta-sleep-inducing peptide reduces CRF-induced corticosterone release Graf MV, Kastin AJ, Coy DH, Fischman AJ, Neuroendocrinology, 1985 · PMID 2995861

  Neuroendocrinology 41(4):353-6. The single best piece of evidence for the HPA-damping mechanism and the reason morning cortisol is on the bloodwork list.

• Entry of DSIP peptides into dog CSF: role of physicochemical and pharmacokinetic parameters Banks WA, Kastin AJ, Coy DH, Angulo E, Brain Research Bulletin, 1986 · PMID 3768731

  Brain Res Bull 17(2):155-8. The best characterisation of how much DSIP actually reaches the central compartment and why.

• Differential penetration of DSIP peptides into rat brain Kastin AJ, Banks WA, Castellanos PF, Nissen C, Coy DH, Pharmacology, Biochemistry, and Behavior, 1982 · PMID 6897680

  Pharmacol Biochem Behav 17(6):1187-91. Establishes that brain entry is partial and structure-dependent.

• Development of an enzyme immunoassay for delta sleep-inducing peptide (DSIP) and its use in the determination of the metabolic clearance rate of DSIP administered to dogs Kato N, Honda Y, Ebihara S, Naruse H, Takahashi Y, Neuroendocrinology, 1984 · PMID 6379493

  Neuroendocrinology 39(1):39-44. The closest thing to a real clearance measurement that exists for this compound, and it is in dogs.

• Evidence for peptide aggregation Kastin AJ, Castellanos PF, Fischman AJ, Proffitt JK, Graf MV, Pharmacology, Biochemistry, and Behavior, 1984 · PMID 6151671

  Pharmacol Biochem Behav 21(6):969-73. Relevant because DSIP aggregation is one explanation for why the old assay literature disagrees with itself so badly.

• Characterization, properties and multivariate functions of delta-sleep-inducing peptide (DSIP) Schoenenberger GA, European Neurology, 1984 · PMID 6548966

  Eur Neurol 23(5):321-45. The discoverer's own summary of the molecule's properties.